• Company
• Leclaza’s lightning fast listing shocks global competitors
• by Eo, Yun-Ho Jan 27, 2021 06:15am

• Policy
• Can COVID-19 vaccine by the COVAX be quickly introduced?
• by Lee, Tak-Sun Jan 27, 2021 06:15am

• Company
• NOAC prescription market growth stagnates
• by Kim, Jin-Gu Jan 27, 2021 06:15am

• Company
• 11 companies won consecutive patent disputes for Betmiga
• by Kim, Jin-Gu Jan 27, 2021 06:15am

• Policy
• AZ’s Vaccine Verification Advisory Committee Meeting held
• by Lee, Tak-Sun Jan 27, 2021 02:24am

• Company
• Sales of Statin-Ezetimibe combination have risen sixfold
• by Chon, Seung-Hyun Jan 27, 2021 02:21am

• Company
• Yuhan’s Leclaza zooms through the NHI listing process
• by Eo, Yun-Ho Jan 26, 2021 06:00am

• Opinion
• [Editor’s View] The key to Xofluza pricing negotiation
• by Nho, Byung Chul Jan 26, 2021 06:00am

• Company
• Antidiabetic DPP-4 inhibitor breaks record of KRW 600 bn
• by Kim, Jin-Gu Jan 26, 2021 06:00am

• Policy
• Nexavar's price drops by 30% & Teribone inj ↑31%
• by Kim, Jung-Ju Jan 25, 2021 06:22am